Affini-T Therapeutics

Affini-T Therapeutics

Edit info

  • Founded: 2021
  • Location: Watertown, MA
  • Employee range: 1-50
  • Clinical stage: Clin0
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: AFNT-111
  • Funding: not disclosed


affinittx.com

linkedin.com

job board


Business:

TCR Cell Therapy

Drug notes:

AFNT-211 Clin0 oncology; AFNT-212 Clin0 oncology; 4 undisclosed programs RD/Clin0 oncology

About:

Affini-T Therapeutics is using the power of T cells to develop therapies for solid tumor cancers. T cells exhibit a cytotoxic response against tumor cells; however, T cells are repressed by the tumor cells in many cancers. Affini-T is using synthetic biology and gene editing to engineer TCR T cell therapies to target oncogenic driver mutations that cause tumors by increasing their activity. Both CD8+ and CD4+ are engineered by Affini-T to further enhance the cytotoxic response and sustained killing of tumor cells as well as to persist longer in the tumor microenvironment. With their discovery platform, Affini-T is building many oncogenic driver programs including KRAS G12V and mutant p53 that are in early development.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com